Eye drops could replace needles for blinding eye disease?
NCT ID NCT06969001
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested the safety of SCAI-005, an eye drop containing axitinib, in 48 healthy Korean adults. The goal was to see if the drug is safe and how it behaves in the body when given as single or multiple doses. It is a first step toward a potential needle-free treatment for wet age-related macular degeneration, a leading cause of vision loss.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
axitinib (as eye drops)
What this could lead to
If this early safety study succeeds, it could pave the way for a non-invasive eye drop treatment for wet age-related macular degeneration, potentially reducing the need for frequent injections.
What could go wrong
This is a very early Phase 1 trial in only 48 healthy people, not patients with the disease. It only tests safety and how the drug moves through the body, not whether it works for wet AMD. Many drugs fail in later stages.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WET AGE RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Catholic University, Seoul ST. Mary's Hospital
Seoul, South Korea